Zacks Research Has Negative Estimate for BMY Q3 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Zacks Research dropped their Q3 2027 earnings estimates for shares of Bristol Myers Squibb in a note issued to investors on Friday, October 23rd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $1.55 per share for the quarter, down from their prior estimate of $1.56. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.51 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.23 EPS and FY2028 earnings at $5.21 EPS.

Several other research firms also recently commented on BMY. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, August 5th. Daiwa Securities Group raised their target price on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Truist Financial restated a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Finally, HSBC reiterated a “hold” rating and set a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $65.50.

Bristol Myers Squibb Trading Up 0.1%

NYSE:BMY opened at $61.56 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $125.75 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The firm’s 50 day moving average is $63.20 and its 200 day moving average is $59.79. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp lifted its holdings in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bristol Myers Squibb by 0.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after buying an additional 520,330 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising cancer-drug data: Bristol Myers Squibb and partners reported that izalontamab brengitecan (Iza-Bren) doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. The drug also showed encouraging results in other solid tumors, strengthening the company’s growth pipeline. Iza-Bren lung cancer trial results
• Positive Sentiment: Breast-cancer progress: Iza-Bren reportedly reduced the risk of disease progression by as much as 38% in a Phase 3 breast-cancer trial. The results could expand the drug’s commercial opportunity and support recent strength in BMY shares. Bristol Myers Squibb cancer breakthrough
• Positive Sentiment: Analyst remains bullish despite target cut: Piper Sandler lowered its price target from $82 to $78 but maintained an “overweight” rating, implying substantial potential upside from the current trading level. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings ahead: Investors are focused on whether growth medicines and stronger Eliquis guidance can offset declines in BMY’s legacy portfolio. The company’s valuation remains relatively modest, with a P/E ratio of 13.56, but earnings execution will be important.
• Negative Sentiment: Lower earnings estimates: Zacks Research reduced its Q3 2027 EPS forecast to $1.55 from $1.56, FY2027 estimates to $6.23 from $6.24, and FY2028 estimates to $5.21 from $5.23. Zacks retains a “Hold” rating, signaling limited near-term conviction.
• Negative Sentiment: Patent-loss risk: Analysts continue to warn that upcoming loss of exclusivity for major drugs could pressure revenue. Investors remain concerned that newer products may not fully replace declining sales quickly enough.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.